KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Tax ProvisionsTax Rate
Others
Ratios

BioNTech SE (BNTX) Share-based Compensation (IS) (2021 - 2025)

Historic Share-based Compensation (IS) for BioNTech SE (BNTX) over the last 5 years, with Q3 2025 value amounting to -$4.9 million.

  • BioNTech SE's Share-based Compensation (IS) rose 9667.34% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$33.4 million, marking a year-over-year increase of 7952.12%. This contributed to the annual value of -$165.1 million for FY2024, which is 7997.32% up from last year.
  • As of Q3 2025, BioNTech SE's Share-based Compensation (IS) stood at -$4.9 million, which was up 9667.34% from -$13.0 million recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's Share-based Compensation (IS) ranged from a high of -$1.7 million in Q3 2022 and a low of -$778.9 million during Q1 2023
  • Moreover, its 5-year median value for Share-based Compensation (IS) was -$5.1 million (2023), whereas its average is -$66.9 million.
  • Its Share-based Compensation (IS) has fluctuated over the past 5 years, first plummeted by 3845663.59% in 2023, then skyrocketed by 9966.53% in 2024.
  • BioNTech SE's Share-based Compensation (IS) (Quarter) stood at -$2.7 million in 2021, then tumbled by 1650.25% to -$48.1 million in 2022, then skyrocketed by 88.8% to -$5.4 million in 2023, then plummeted by 116.51% to -$11.6 million in 2024, then soared by 57.85% to -$4.9 million in 2025.
  • Its Share-based Compensation (IS) was -$4.9 million in Q3 2025, compared to -$13.0 million in Q2 2025 and -$3.8 million in Q1 2025.